Forget Zepbound: Lilly's Next Stock Signal for Investors
Lilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
Lilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
Grail's stock has slid as its Galleri MCED test faced a major trial setback. This piece breaks down what happened, wh...